Amgen

News

OpenAI introduces GPT-Rosalind, its drug discovery AI

In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

Amgen's BiTE for lung cancer backed for EU approval

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

Market Access

A panel on direct-to-patient at Reuters Pharma USA

In DTC's watershed moment, trust and partnership are key

More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.

News

Amgen baulks at FDA request to withdraw Tavneos

Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated vasculitis from the US market.

OpenAI introduces GPT-Rosalind, its drug discovery AI

Amgen scores with new thyroid eye disease formulation

FDA points to liver injury with Amgen's Tavneos

Amgen's BiTE for lung cancer backed for EU approval

In DTC's watershed moment, trust and partnership are key

Amgen baulks at FDA request to withdraw Tavneos

Agios shares slide as it abandons sickle cell candidate

Discover a new era of healthcare panel engagement: Grounded ...

Amgen

Editor's Picks